Aviso Financial Inc. Has $3.07 Million Position in Cencora, Inc. $COR

Aviso Financial Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 16.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,231 shares of the company’s stock after acquiring an additional 1,462 shares during the period. Aviso Financial Inc.’s holdings in Cencora were worth $3,068,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. Quadcap Wealth Management LLC raised its position in shares of Cencora by 1.5% in the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares during the period. CreativeOne Wealth LLC grew its stake in Cencora by 8.0% in the 2nd quarter. CreativeOne Wealth LLC now owns 6,099 shares of the company’s stock valued at $1,829,000 after buying an additional 454 shares during the last quarter. Summit Global Investments raised its holdings in Cencora by 187.1% in the 2nd quarter. Summit Global Investments now owns 4,553 shares of the company’s stock valued at $1,365,000 after acquiring an additional 2,967 shares during the period. Jefferies Financial Group Inc. raised its holdings in Cencora by 130.5% in the 2nd quarter. Jefferies Financial Group Inc. now owns 50,706 shares of the company’s stock valued at $15,204,000 after acquiring an additional 28,706 shares during the period. Finally, Global Retirement Partners LLC acquired a new stake in Cencora during the second quarter worth approximately $6,817,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Robert W. Baird increased their price objective on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group boosted their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 46,640 shares of company stock worth $14,099,338 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Cencora Trading Up 1.7%

Shares of COR opened at $371.99 on Tuesday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $372.78. The firm has a market cap of $72.12 billion, a price-to-earnings ratio of 38.27, a PEG ratio of 1.56 and a beta of 0.63. The business’s fifty day moving average is $329.29 and its 200-day moving average is $305.29.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the firm posted $3.34 earnings per share. Cencora’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Cencora’s payout ratio is presently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.